Citizens Financial Group Inc. RI Sells 24,708 Shares of Pfizer Inc. $PFE

Citizens Financial Group Inc. RI lowered its stake in Pfizer Inc. (NYSE:PFE) by 6.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 367,335 shares of the biopharmaceutical company’s stock after selling 24,708 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $8,904,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC boosted its stake in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company’s stock valued at $328,000 after buying an additional 388 shares during the last quarter. Citizens National Bank Trust Department raised its holdings in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares in the last quarter. Able Wealth Management LLC boosted its position in shares of Pfizer by 2.0% during the 2nd quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after acquiring an additional 413 shares during the last quarter. Trust Co of the South grew its holdings in shares of Pfizer by 1.5% in the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company’s stock valued at $712,000 after purchasing an additional 441 shares in the last quarter. Finally, Charter Oak Capital Management LLC increased its position in Pfizer by 4.3% in the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 444 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 2.8%

Shares of NYSE PFE opened at $25.08 on Monday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The firm has a 50-day simple moving average of $24.80 and a two-hundred day simple moving average of $24.45. The company has a market cap of $142.57 billion, a P/E ratio of 13.34, a PEG ratio of 0.81 and a beta of 0.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analyst Weigh In

PFE has been the subject of several research reports. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Scotiabank initiated coverage on shares of Pfizer in a report on Thursday. They issued a “sector outperform” rating and a $30.00 price target for the company. The Goldman Sachs Group reissued a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Finally, Bank of America lifted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.